Showing results (541-550 of 630) with videos related to
Sort By:
Pageof 63
Dermatitis : Contact, Atopic, Occupational, Drug|August 17, 2023
Patch Test Results Among Older Adults: A Retrospective Analysis of the North American Contact Dermatitis® Group Data (2009-2020)JiaDe Yu, Hadley Johnson, Joel G DeKoven, et al.Immunotherapy|November 15, 2021
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summaryThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.Dermatitis : Contact, Atopic, Occupational, Drug|January 14, 2022
Shoe Allergens: A Retrospective Analysis of Cross-sectional Data From the North American Contact Dermatitis Group, 2005-2018Amber Reck Atwater, Raina Bembry, Cynthia L Green, et al.Dermatitis : Contact, Atopic, Occupational, Drug|September 27, 2021
Patch Testing to Ethylhexylglycerin: The North American Contact Dermatitis Group Experience, 2013-2018Erin M Warshaw, Michele Buonomo, Howard I Maibach, et al.Dermatitis : Contact, Atopic, Occupational, Drug|March 6, 2021
Patch Testing to Methyldibromoglutaronitrile/Phenoxyethanol: North American Contact Dermatitis Group Experience, 1994-2018Erin M Warshaw, Michele Buonomo, Joel G DeKoven, et al.The New England Journal of Medicine|March 24, 2021
Abrocitinib versus Placebo or Dupilumab for Atopic DermatitisThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|January 18, 2023
Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent eventsR Bissonnette, L F Eichenfield, E Simpson, et al.Journal of the American Academy of Dermatology|August 8, 2022
Hand and foot dermatitis in patients referred for patch testing: Analysis of North American Contact Dermatitis Group Data, 2001-2018Jonathan I Silverberg, Nisha Patel, Erin M Warshaw, et al.Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.American Journal of Clinical Dermatology|March 26, 2024
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)Jonathan I Silverberg, Melinda J Gooderham, Amy S Paller, et al.Pageof 63